Strides Pharma re-launches Ranitidine tablets (Rx) for US market

08 Nov 2019 Evaluate

Strides Pharma Science has re-launched Ranitidine tablets for the US market. Strides’ Ranitidine Tablets 300 mg (Rx) were within the acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm. The company has now completed comprehensive testing of several of its batches available in market and in stock meeting the limits prescribed by the USFDA. Basis the outcome company has decided to relaunch its product with immediate effect. 

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

943.05 -24.50 (-2.53%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×